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OBJECTIVE: To describe the evolution and outcome of children hospitalized with community-acquired pneumonia
receiving penicillin .
METHODS: A search was carried out for all hospitalized community-acquired pneumonia cases in a 37-month
period. Inclusion criteria comprised age $2 months, intravenous penicillin G use at 200,000 IU/kg/day for $48 h and
chest x-ray results. Confounders leading to exclusion included underlying debilitating or chronic pulmonary
illnesses, nosocomial pneumonia or transference to another hospital. Pneumonia was confirmed if a pulmonary
infiltrate or pleural effusion was described by an independent radiologist blind to the clinical information. Data on
admission and evolution were entered on a standardized form.
RESULTS: Of 154 studied cases, 123 (80%) and 40 (26%) had pulmonary infiltrate or pleural effusion, respectively.
Penicilli was substituted by other antibiotics in 28 (18%) patients, in whom the sole significant decrease was in the
frequency of tachypnea from the first to the second day of treatment (86% vs. 50%, p=0.008). Among patients
treated exclusively with penicillin G, fever (46% vs. 26%, p=0.002), tachypnea (74% vs. 59%, p=0.003), chest
indrawing (29% vs. 13%, p,0.001) and nasal flaring (10% vs. 1.6%, p=0.001) frequencies significantly decreased
from admission to the first day of treatment. Patients treated with other antimicrobial agents stayed longer in the
hospital than those treated solely with penicillin G (16¡6 vs. 8¡4 days, p,0.001, mean difference (95% confidence
interval) 8 (6–10)). None of the studied patients died.
CONCLUSION: Penicillin G successfully treated 82% (126/154) of the study group and improvement was marked on
the first day of treatment.
KEYWORDS: Acute respiratory infection; Antibiotic; Beta-lactams, Lower respiratory tract infection; Treatment
success.
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INTRODUCTION
Community-acquired pneumonia (CAP) remains a sig-
nificant cause of childhood deaths in developing countries.1
Moreover, it is a common cause of hospitalization world
wide, which is an economic burden for the healthcare
system.2 Use of antibiotics is the main strategy used to
overcome children’s morbidity and mortality in such
circumstances.3 Mortality from CAP in children dramati-
cally decreased in the United States when penicillin
was introduced into daily practice in comparison with
the pre-antibiotic era.4 In order to control the situation in
developing countries, the World Health Organization
(WHO) proposed standardized procedures to diagnose
and treat children with CAP.5 In such an algorithm, it is
recommended that penicillin G is given to children
hospitalized with severe CAP.6 The rationale for such a
choice in treating bacterial CAP is the presence of Strep-
tococcus pneumoniae, which is the main target.7 Never-
theless, the use of combination therapy, by adding an
antibiotic from another class to beta-lactams, has been advo-
cated as a better option for treating pneumococcal severe
CAP.8 In addition, different medical societies have recom-
mended the empirical use of other beta-lactams besides
penicillin G for treating children with severe CAP.9,10
In this context, we aimed to describe the evolution and
outcome of the illness in children aged $2 months
hospitalized with radiographically diagnosed CAP treated
with intravenous aqueous penicillin G at the daily dose of
200,000 IU/kg.
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MATERIALS AND METHODS
This was a retrospective cohort of CAP cases treated in
the university hospital, from October 2002 to October 2005.
Based on the hospital admittance log book, the same
researcher identified each child hospitalized with CAP.
The inclusion criteria comprised children aged $2 months
hospitalized with CAP treated intravenously with
200,000 IU/kg/day of aqueous penicillin G for at least 48 h
and with readable chest x-ray results. The exclusion criteria
were underlying debilitating conditions such as heart
disease with hemodynamic repercussion, chronic lung
disease except asthma, including chronic pulmonary infec-
tions, primary or secondary immunodeficiency, nosocomial
pneumonia from another hospital or transfer to another
hospital during penicillin G treatment.
A pediatric radiologist, a member of this research project
team, read the chest x-ray findings blind to the clinical
information. The final radiographic diagnosis of pneumonia
was based on the presence of pulmonary infiltrate or pleural
effusion on the chest x-ray taken on admission after
considering the standardized interpretation previously
published.11 Data on demographics, clinical history and
physical examination on admission, treatment, daily evolu-
tion during the first 7 days of treatment and outcome were
collected from the medical chart and recorded on a
standardized form. For axillary temperature and respiratory
rate (RR), the highest grade recorded on the medical chart
was collected. Fever was defined as an axillary temperature
.37.5 C˚,12 and tachypnea as RR $50 breaths/min in
children aged 2–11 months and RR $40 breaths/min in
children from $12 months.13 Nutritional evaluation was
performed using the software Anthro, version 1.02 (CDC
and WHO) and severe malnutrition was defined as a Z-
score for weight-for-age index under 23.00 using the
National Centre for Health Statistics (NCHS-USA) stan-
dard.14 CAP was classified as non-severe, severe or very
severe according to WHO guidelines: patients with chest
indrawing were classified as severe CAP and patients with
somnolence, seizures, grunting when calm, nasal flaring,
cyanosis, or inability to drink were classified as very severe
CAP.13 CAP severity was assessed according to the British
Thoracic Society (BTS) guidelines: RR .70 breaths/min for
infants, RR .50 breaths/min for older children, difficulty in
breathing, dehydration, or axillary temperature .39 C˚
classified the case as severe CAP.10
The results are described by reporting the distribution.
Categorical variables between different groups of patients
were compared using x2 or Fisher’s exact test, as appro-
priate. Continuous variables were compared using Student t
test or Mann–Whitney U test, as appropriate and the mean
difference with the respective 95% confidence interval was
calculated. The daily frequency of clinical findings was
compared using McNemar test. The statistical tests were
two tailed, with a significance level of 0.05. The statistical
software SPSS (version 9.0) was used for analysis. The study
was approved by the ethics committee.
RESULTS
A total of 456 children were examined. Exclusion was due
to underlying chronic debilitating conditions (n = 86) or
nosocomial pneumonia from another hospital (n = 16).
Among the other 354 cases, pneumonia was radiographi-
cally confirmed in 154 (43.5%). The flow chart of the study is
shown in Figure 1. None of the enrolled cases died. The
study group comprised 154 patients who received
200,000 IU/kg/day of aqueous penicillin G divided into 4
daily doses. Besides the included patients, 27 patients aged
, 2 months and 43 patients aged $ 2months receiving other
antimicrobial agents were hospitalized with radiographi-
cally confirmed pneumonia in the study period.
The median age (months) was 24 months (mean 32¡25
months, range 68 days–11.5 years) and 38 (24.7%) patients
were younger than 1 year. There were 92 (59.7%) males.
According to WHO criteria, severe and very severe CAP was
present in 46 (29.9%) and 19 (12.3%) cases, respectively. The
frequency of the severity criteria items was: chest indrawing
(29.9%), nasal flaring (9.1%), grunting (3.9%), somnolence
(1.3%), seizure (0.6%), cyanosis (0.6%). Nobody was unable to
drink. According to BTS criteria, severe CAP occurred in 107
(69.5%) patients and the frequency of the additional items
was: RR .70 breaths/min for infants (21.1%), RR .50
breaths/min for older children (38.3%), difficulty breathing
(48.1%), axillary temperature .39 C˚ (9.2%). On admission,
the most common complaints were cough (99.2%), fever
(97.2%), difficulty in breathing (56.5%), and findings were
tachypnea (75.2%), fever (49.7%) and crackles (33.8%). Severe
malnutrition was diagnosed in 6 (3.9%) cases. Pulmonary
infiltrate and pleural effusion were detected in 123 (80.0%)
and 40 (26.0%) cases, respectively; pulmonary infiltrate was
categorized as alveolar (95.1%), interstitial (1.6%) or alveolar–
interstitial (3.3%); other radiographic findings were peri-
bronchial thickening (5.8%) and atelectasis (4.5%). There was
no abscess, hyperinflation, pneumothorax, or pneumatocele.
Overall, the duration of hospitalization (days), median
(25th–75th percentile) and mean¡ standard deviation, were
8 (5–11) and 9¡6 (range 2–31), respectively. The median
(25th–75th percentile) duration of penicillin administration
was 4 (3–7) days (mean 5¡3, range 2–17). A rapid-acting
inhaled bronchodilator (63.0%), short course of systemic
corticosteroids (24.0%), intravenous hydration (saline solu-
tion plus 5% dextrose in water (1:4)) (66.2%) and oxygen
(6.5%) were also given on admission.
Table 1 shows an assessment of the frequency of overall
clinical findings during the first 2 days of penicillin G
treatment. Nobody presented seizure. Oxygen was pro-
vided during the evolution to 16 (11.1%) patients of 144
admitted without initial oxygen supplement requirement.
Penicillin G was substituted by other antibiotics in 28
(18.2%) patients, among whom the median (25th–75th
percentile) duration of penicillin G administration was 3.5
(2-4) days (mean 4¡2). The subsequent antimicrobial agents
were oxacillin plus ceftriaxone (n = 11), ceftriaxone (n = 11),
erythromycin and oxacillin (n = 3 each). Patients treated
with other antimicrobial agents stayed longer in the hospital
than those treated solely with penicillin G (16¡6 vs. 8¡4
days, p,0.001, mean difference (95% confidence interval): 8
(6-10]). Oxygen supplement during evolution was more
common among patients in whom substitution for penicillin
G occurred (26.9% vs. 7.6%, p = 0.01).
Comparison of the daily frequency of clinical findings in
this group showed that the only significant difference was
tachypnea from the first to second day of treatment (86.4%
vs. 50.0%, p = 0.008). Among patients receiving only
penicillin G during the whole treatment, significant differ-
ences were found between admission and first day of
treatment: fever (46.4% vs. 26.3%, p = 0.002), tachypnea
(73.6% vs. 59.4%, p = 0.003), chest indrawing (29.4% vs.
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12.7%, p,0.001) and nasal flaring (10.2% vs. 1.6%, p = 0.001).
Differences were also found in the frequency of fever
between the second and third day (26.8% vs. 13.7%,
p = 0.001) and between the fourth and fifth day (17.8% vs.
10.3%, p = 0.006). Figures 2A and 2B present the daily
evolution of clinical findings in the groups of patients
without and with penicillin G substitution after 48 h of
treatment. Antibiotic change was not associated with
pleural effusion (25.0% vs. 15.8%, p = 0.2), severe (19.6%
vs. 17.6%, p = 0.8) or very severe (15.8% vs. 18.5%, p = 1)
CAP according to WHO, severe CAP according to BTS
(18.7% vs. 17.0%, p = 0.8), severe malnutrition (16.7% vs.
18.2%, p = 1) or age (38¡29 vs. 30¡24 months, p = 0.2).
DISCUSSION
From the aforementioned data it can be seen that aqueous
penicillin G successfully treated the great majority (82%) of
the studied hospitalized children aged $2 months with
radiographically confirmed CAP. This result is in accor-
dance with the expected therapeutic success rate (80%).15
Among children receiving solely penicillin G, marked
recovery occurred during the first 24 h of treatment. A rapid
and uneventful improvement has been described among
children hospitalized with CAP treated mainly with
penicillin G in a developed country.16 Surprisingly, after
the major impact of a decreased frequency of clinical
findings from admission to the first day of treatment,
further reduction of these clinical findings was slow in the
same group of patients (Figure 2A). Based on expert
consensus, if no improvement takes place within 2 days of
treatment, the recommendation is to review the antibacterial
treatment given.17 In the literature, there is no clear
evidence-based definition of treatment failure among
children with CAP, mainly for hospitalized patients.15 In a
study enrolling patients with non-severe and severe CAP, in
Figure 1 - Flow chart of the study group enrollment for the community-acquired pneumonia retrospective longitudinal study in
Salvador, Northeast Brazi. CAP, community-acquired pneumonia; CXR, chest x-ray.
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addition to deterioration, no improvement after 48 h of
therapy was used as the definition of clinical failure.18 By
applying such a definition to the patients in this investiga-
tion, the therapeutic failure rate of penicillin G would be
much greater since on the fourth day of treatment over 40%
presented tachypnea and around 20% presented fever
(Figure 2A). Moreover, on the sixth day of treatment, over
30% still presented tachypnea (Figure 2A).
We found an association between the requirement for an
oxygen supplement during treatment and penicillin G
substitution. Therefore, the concept of deterioration was
used by the pediatricians managing the studied patients.
However, the concept of no improvement in the first 2 days
of treatment was not used. By comparing the graphic
evolution of children in whom penicillin G had been
changed with the group receiving solely penicillin G
Table 1 - Assessment of the frequency of clinical findings during the first 2 days of penicillin G treatment among
children hospitalized with community-acquired pneumonia.
Day of evaluation* Statistical analysis (p)
Clinical findings On admission Day 1 Day 2 On admission 3 day 1 Day 1 3 day 2
Fever 76/153 (49.7) 44/122 (36.1) 50/140 (35.7) 0.008 1.0
Tachypnea 115/153 (75.2) 79/123 (64.2) 67/132 (50.8) 0.004 0.005
Chest indrawing 46/154 (29.9) 17/154 (11.0) 15/154 (9.7) , 0.001 0.8
Nasal flaring 14/154 (9.1) 3/154 (1.9) 1/154 (0.6) 0.003 0.6
Grunting 6/154 (3.9) 0 0 0.03 -
Somnolence 2/154 (1.3) 1/154 (0.6) 2/154 (1.3) 1.0 1.0
Cyanosis 1/154 (0.6) 0 2/154 (1.3) 1.0 0.5
*Results are shown as n/N (%).
Figure 2A - Daily evolution (%) of (A) 126 children hospitalized with community-acquired pneumonia treated exclusively with penicillin
G and (B) 28 children hospitalized with community-acquired pneumonia in whom penicillin G was substituted by other antimicrobial
agents after 2 days of us.
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(Figures 2A and B), it can be seen that fever and tachypnea
were steadily present during the studied period in the
former group. Despite the statistical significance found for
the decrease of tachypnea from the first to the second day of
treatment in the former group, the increased frequency of
tachypnea on the third day of treatment is in accordance
with the observation of a marked absence of improvement
among those patients.
The absence of an association between change of
penicillin G and baseline aspects of the patient, such as
age, severe or very severe CAP or severe malnutrition, was
noteworthy. Severity has been identified as a risk factor for
treatment failure among adults with CAP.19 Nonetheless,
this was not found in this study. Moreover, pleural effusion
was not associated with change of penicillin G. The main
cause of bacterial CAP, S pneumoniae, has been identified as
the most common bacterium among children with CAP and
pleural effusion.20 As a retrospective survey, this investiga-
tion was influenced by the way in which the pediatrician
handled the patients. Penicillin G has been widely used in
the setting in which this survey was carried out because of
the previous use of an investigational protocol on the
association of pneumococcal resistance in vitro with peni-
cillin G failure in vivo (the CARIBE Study).21 Although the
data for the latter protocol were collected between 1998 and
2000, data collection for our investigation included children
hospitalized from 2002 to 2005. As the CARIBE Study
concluded that there is no association between penicillin G
therapeutic failure and pneumococcal minimal inhibitory
concentration up to 4 mg/mL,22 pediatricians are probably
confident about the success of penicillin G. By studying the
pharmacokinetics of 200,000 IU/kg/day of penicillin G in
children with CAP, serum penicillin G concentrations were
.4 mg/mL for .40% of the interdose interval,23 which
predicts therapeutic success in treating pulmonary infec-
tions caused by pneumococcal strains with minimal
inhibitory concentration up to 4 mg/mL.24 In Brazil, up to
the present, the highest minimal inhibitory concentration
described for pneumococcal strains is 4 mg/mL, which is
rare.25
Several methodological limitations should be recognized
in this study: first, as data were collected retrospectively,
there was no control on the measurement of the variables;
second, as the patients were evaluated by different
observers, standardization of the evaluations cannot be
guaranteed; third, no attempt was made to determine the
etiology and the causative agents of CAP were not known.
Nevertheless, strict enrolment criteria were used, assuring
that each included case had CAP defined by the ‘‘gold
standard’’ parameter—chest x-ray diagnosis. Moreover, by
taking into account that 26% of the cases presented pleural
effusion and 98.4% of the pulmonary infiltrates were
described as alveolar (95.1% as alveolar and 3.3% as
interstitial–alveolar), the assumption was that the majority
of the cases had a bacterial etiology.11 As the patients were
hospitalized in a teaching hospital where several research
projects on CAP have been conducted during the past 13
years,26 it is highly probable that standardized measures
were used. In daily practice, an antibiotic is chosen
empirically to treat children with CAP and etiology is
rarely established.17 Therefore, the results presented herein
may be generalized to similar situations.
In conclusion, penicillin G is highly effective in treating
children hospitalized with CAP. Since patients’ disease does
not deteriorate during treatment, observation may continue
for more than 48 h to document clinical improvement.
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